Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eylea for retinal non-perfusion in proliferative diabetic retinopathy
NCT02863354Phase 2Completed
- Sponsor
- Charles C. Wykoff
- Start
- Aug 2016
- Primary completion
- May 2019
- Modality
- Engineered Antibody Formats, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of aflibercept in proliferative diabetic retinopathy (PDR), sponsored by Charles C. Wykoff. Started Aug 2016; status: completed.
02
Drugs
aflibercept
03
Conditions
proliferative diabetic retinopathy (PDR)
Beyond the preview
Go deeper on NCT02863354.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02863354.